| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H20N6O |
| Molecular Weight | 264.3268 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC=NC2=C1N=CN2CCNCCCCCO
InChI
InChIKey=CVPTTZZCRDVGSU-UHFFFAOYSA-N
InChI=1S/C12H20N6O/c13-11-10-12(16-8-15-11)18(9-17-10)6-5-14-4-2-1-3-7-19/h8-9,14,19H,1-7H2,(H2,13,15,16)
| Molecular Formula | C12H20N6O |
| Molecular Weight | 264.3268 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
NB-001, an oil-in-water emulsion containing high energy nanometer-sized droplets stabilized by surfactants is designed for topical treatment of herpes labialis infections. NB-001 diffuses through the stratum corneum via the follicular route to accumulate in the epidermal and dermal tissues, without disrupting the normal epithelial matrix. The concentrations achieved in the epidermis and dermis are well above the concentrations required for antiviral activity.
Originator
Approval Year
Doses
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
Subjects applied 200 µL of NB-001 (0.1%, 0.3%, 0.5%) 5 times daily for a maximum of 4 days.
Route of Administration:
Topical
Strains of HSV-1and HSV-2 (3 x 105 - 7.5 x 106 pfu/ml) were exposed to different concentrations of NB-001 for 15 minutes at room temperature and residual live virus was measured in a standard plaque-forming assay. The IC95 values of NB-001 against either HSV-1 or -2 virus ranged from 3 - 14 μg/ml.
